NCT05524155

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Safety and Efficacy of Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis Who Failed Second-line Therapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy

Conditions

• Colorectal Cancer
• Liver Metastasis

Interventions

Type	Name	Description
DRUG	HAIC	hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
DRUG	Sintilimab	200mg IV d1,Q3W
DRUG	Regorafenib	80mg/day,PO,QD,d1～21,Q4W

Timeline

• Start date: 2022-09-01
• Primary completion: 2024-03-01
• Completion: 2024-12-01
• First posted: 2022-09-01
• Last updated: 2022-09-01